Hidesaku Asakura

Dr. Hidesaku Asakura

Kanazawa university Hospital
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2020 in International Journal of Hematology
Verified
Journal Article
Open access
PDF file
HAHidesaku Asakura
Hidesaku Asakura
HOHaruhiko Ogawa
Haruhiko Ogawa
The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in d-dimer, and its relationship with prognosis has been discussed. However, limits exist to the utility of evaluation by d-dimer alone. In addition, since the coagulation/fibrinolytic condition sometimes fluctuates within a short period of time, regular examinations in recognition of the significance of the examination are desirable. The pathophysiology of disseminated intravascular coagulation (DIC) associated with COVID-19 is very different from that of septic DIC, and both thrombotic and hemorrhagic pathologies should be noted. COVID-19 thrombosis includes macro- and microthrombosis, with diagnosis of the latter depending on markers of coagulation and fibrinolysis. Treatment of COVID-19 is classified into antiviral treatment, cytokine storm treatment, and thrombosis treatment. Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further study

6 March 2014 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
HAHidesaku Asakura
Hidesaku Asakura
Disseminated intravascular coagulation (DIC) has a common pathogenesis in terms of persistent widespread activation of coagulation in the presence of underlying disease, but the degree of fibrinolytic activation often differs by DIC type. DIC with suppressed fibrinolysis is a DIC type usually seen in sepsis. Coagulation activation is severe, but fibrinolytic activation is mild. DIC with enhanced fibrinolysis is a DIC type usually seen in acute promyelocytic leukemia (APL). Both coagulation activation and fibrinolytic activation are severe. DIC with balanced fibrinolysis is a DIC type usually seen in solid tumors, with an intermediate pathogenesis between the above two types. In animal DIC models, lipopolysaccharide (LPS)-induced models are similar to suppressed-fibrinolytic-type DIC, whereas tissue factor (TF)-induced models are similar to enhanced fibrinolytic/balanced fibrinolytic DIC. Appropriate diagnosis and treatment may also differ depending on the DIC type.

28 September 2016 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
DHDic Subcommittee Of The Japanese Society On Thrombosis And Hemostasis
Dic Subcommittee Of The Japanese Society On Thrombosis And Hemostasis
HAHidesaku Asakura
Hidesaku Asakura
HTHoyu Takahashi
Hoyu Takahashi
TUToshimasa Uchiyama
Toshimasa Uchiyama
YEYUTAKA EGUCHI
YUTAKA EGUCHI
Hideo WadaHideo Wada
Hideo Wada
Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of underlying disease, causes persistent, generalized, marked coagulation activation. Early treatment based on an appropriate diagnosis is very important for improving patients’ prognosis, to which end diagnostic criteria play a key role. Several criteria have been proposed, but each has its strengths and weaknesses, and improved criteria are needed. Widespread use of coagulofibrinolytic markers has elucidated that the pathology of DIC differs greatly as a function of the underlying disease. Thus, discriminating use of DIC diagnostic criteria that take underlying diseases into account is important. DIC diagnostic criteria that are well known in Japan include the Japanese Ministry of Health and Welfare’s old DIC diagnostic criteria (JMHW criteria), the International Society on Thrombosis and Haemostasis’s DIC diagnostic criteria (ISTH criteria), and the Japanese Association for Acute Medicine’s acute-stage DIC diagnostic criteria (JAAM criteria). Those criteria have their respective drawbacks: the sensitivity of the ISTH criteria is poor, the JAAM criteria cannot be applied to all underlying diseases, and the JMHW criteria have poor sensitivity in the case of infections, do not use molecular markers, and result in misdiagnosis. The Japanese Society on Thrombosis and Hemostasis’s newly proposed provisional draft DIC diagnostic criteria (new criteria) use diagnostic criteria classifications of “hematopoietic disorder type”, “infectious type”, and “basic type” based on the underlying pathology. For the hematopoietic disorder type the platelet count is omitted from the score, while for the infectious type, fibrinogen is omitted from the score. Also, points are added if the platelet count decreases with time. In the new criteria, molecular markers and antithrombin activity have been newly included, and as a countermeasure for misdiagnosis, 3 points are deducted if there is liver failure. In this paper, we discuss various problems encountered with DIC diagnosis, and we describe the new criteria together with the events that led to their creation. These new diagnostic criteria take into account the underlying diseases of wide area, and we expect that they will serve clinicians well due to the above adaptations and improvements.

14 September 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
Toshiaki IbaToshiaki Iba
Toshiaki Iba
MNMarcello Di Nisio
Marcello Di Nisio
JTJecko Thachil
Jecko Thachil
Hideo WadaHideo Wada
Hideo Wada
HAHidesaku Asakura
Hidesaku Asakura
DSDaizoh Saitoh
Daizoh Saitoh
With advances in the treatment of sepsis, the systemic inflammatory response syndrome (SIRS) has been losing its prognostic power. Since the SIRS category is no longer used for the diagnosis of sepsis, the disseminated intravascular coagulation (DIC) diagnostic criteria released by Japanese Association for Acute Medicine (JAAM) should be modified. Thus, the purpose of this study was to examine the appropriateness of replacing the SIRS score with antithrombin activity in JAAM-DIC diagnostic criteria. We analyzed data from 819 septic patients who had received recombinant thrombomodulin. The relationships between the 28-day mortality rate and baseline laboratory and clinical parameters were examined using univariate and multivariate analyses, and the impact of replacing the SIRS criteria with antithrombin activity was evaluated. The SIRS score, prothrombin time ratio, and antithrombin activity were associated with the 28-day mortality rate (P values = 0.013, 0.018, and 0.003, respectively, by multivariate analysis). A modified version of the JAAM-DIC diagnostic criteria using an antithrombin activity <70 % was capable of diagnosing the identical number (n = 706) and a similar severity of patients (mortality, 34.6 % versus 34.8 %). Since anticoagulant therapy is expected to be more effective in patients with more severe coagulation disorders, the modified version of the JAAM-DIC diagnostic criteria might be useful for discriminating patients with sepsis who are good candidates for anticoagulant therapy.

3 July 2017 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
DHDic Subcommittee Of The Japanese Society On Thrombosis And Hemostasis
Dic Subcommittee Of The Japanese Society On Thrombosis And Hemostasis
Hideo WadaHideo Wada
Hideo Wada
HTHoyu Takahashi
Hoyu Takahashi
TUToshimasa Uchiyama
Toshimasa Uchiyama
YEYUTAKA EGUCHI
YUTAKA EGUCHI
HAHidesaku Asakura
Hidesaku Asakura
As proposed diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis has been approved and revised, the contents and changes are informed.

1 January 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
WTWakana Takahashi
Wakana Takahashi
TYTaro Yoneda
Taro Yoneda
HKHayato Koba
Hayato Koba
TUTsukasa Ueda
Tsukasa Ueda
NTNoriaki Tsuji
Noriaki Tsuji
HAHidesaku Asakura
Hidesaku Asakura
• Antiviral treatment did not show efficacy for hypoxemia and DIC in a COVID-19 patient. • Heparin and nafamostat combination therapy showed dramatic efficacy on the illness. • Mechanisms by which nafamostat is effective for COVID-19 have been fully explained. • This would be an instructional lecture on nafamostat therapy for COVID-19 patients.